A BACTERIOPHAGE MODEL BASED ON CRISPR/CAS IMMUNE SYSTEM IN A CHEMOSTAT

Mengshi Shu, Rui Fu and Wendi Wang*

Key Laboratory of Eco-environments in Three Gorges Reservoir Region
School of Mathematics and Statistics, Southwest University
Chongqing 400715, China

Abstract. Clustered regularly interspaced short palindromic repeats (CRISPRs) along with Cas proteins are a widespread immune system across bacteria and archaea. In this paper, a mathematical model in a chemostat is proposed to investigate the effect of CRISPR/Cas on the bacteriophage dynamics. It is shown that the introduction of CRISPR/Cas can induce a backward bifurcation and transcritical bifurcation. Numerical simulations reveal the coexistence of a stable infection-free equilibrium with an infection equilibrium, or a stable infection-free equilibrium with a stable periodic solution.

1. **Introduction.** Bacteriophage or virulent phage is a virus which can grow and replicate by infecting bacteria. Once residing in bacteria, phage grow quickly, which result in the infection of bacteria and drive the bacteria to die [17]. Thus, we can view them as bacteria predators and use them to cure the diseases induced by infecting bacteria [9,35]. Phage therapy has become a promising method because of the emergence of antibiotic resistant bacteria [9,12]. Indeed, as a treatment, phages have several advantages over antibiotics. Phages replicate and grow exponentially, while antibiotics are not [47]. Generally speaking, a kind of phages infect only particular classes of bacteria, and this limitation of their host is very beneficial to cure the diseases. Moreover, phages are non-toxic, and cannot infect human cells. Hence, there are fewer side effects as compared to antibiotics [12,35].

It is important to understand the interaction dynamics between bacteria and phage to design an optimal scheme of phage therapy. There have been a number of papers that study the mathematical models of bacteriophages (see, for example, [1–4, 8–11, 21, 23, 28, 42] and the references cited therein). Campbell [11] proposed a deterministic mathematical model for bacteria and phage, which is a system of differential equations containing two state variables, susceptible bacteria S and phage P, and incorporating a delay τ that represents the time period for phage replication in the bacteria. The model was developed by [28, 32, 36, 40] to consider the effect of predation and competition with the limited resources. It was further studied by [3,4,21] to study the infections of marine bacteriophages, where bacteria populations from 5-6% up to 70% are infected by bacteriophages [38]. Smith and Thieme [42] formulate two models: a system of delay differential equations with

---

infinite delay and a more general infection-age model that leads to a system of integro-differential equations to study the persistence of bacteria and phage.

It was observed that phage can exert pressure on bacteria to make them produce resistance through loss or modification of the receptor molecule to which a phage binds with an inferior competition ability for nutrient uptake [25]. More recently, biological evidences are found that there exists an adaptive immune system across bacteria, which is the Clustered regularly interspaced short palindromic repeats (CRISPRs) along with Cas proteins [6, 13, 14, 18, 26, 27, 31, 41]. In this system, phage infection is memorized via a short invader sequence, called a proto-spacer, and added into the CRISPR locus of the host genome. And, the CRISPR/Cas system admits heritable immunity [13, 14, 18, 26, 31]. The replication of infecting phage in bacteria is aborted if their DNA matches the crRNAs (CRISPR RNAs) which contains these proto-spacer. On the other hand, if there is no perfect pairing between the proto-spacerand the foreign DNA (as in the case of a phage mutant), the CRISPR/Cas system is counteracted and replication of the phage DNA can occur [19, 33, 34, 39]. Therefore, the CRISPR/Cas system participates in a constant evolutionary battle between phage and bacteria [7, 13, 27, 47].

Mathematical models are powerful in understanding the population dynamics of bacteria and phages. Han and Smith [23] formulated a mathematical model that includes a phage-resistant bacteria, where the resistant bacteria is an inferior competitor for nutrient. Their analytical results provide a set of sufficient conditions for the phage-resistant bacteria to persist. Recently, mathematical models have been proposed to study the contributions of adaptive immune response from CRISPR/Cas in bacteria and phage coevolution [27, 29]. In these papers, numerical simulations are used to find how the immune response affects the coexistence of sensitive strain and resistance strain of bacteria. In the present paper, we extend the model in [23] by incorporating the CRISPR/Cas immunity on phage dynamics. Following [23], we focus on five state variables: R, S, M, I and P which represent the concentrations of nutrient, sensitive bacteria and resistant bacteria, productively infected bacteria and phage in a chemostat. The following assumptions will be used in the formulation of mathematical model: (i) all sensitive bacteria have the potential to get the acquired immunity; (ii) only the resistance from the CRISPR/Cas immunity is considered, which is incomplete because phage can mutate under the pressure of CRISPR/Cas immunity; the resistant bacteria suffer the cost of competitive ability [28]; (iii) the infected bacteria don't uptake nutrient, and cannot be infected again [23]; (iv) the latent time for phage infection is omitted because it is small; (v) the loss of phage due to multiple phage attachment to bacteria is omitted.

Let k be the valid phage adsorption rate to both susceptible and resistant bacteria, which is reasonable because the CRISPR/Cas immunity does not interfere with phage adsorption. Following [23], we let the loss rates of phages due to adsorption to susceptible bacteria and resistant bacteria be described by kSP and kMP respectively, and the infection rate of sensitive bacteria be given by kSP. Note that the CRISPR/Cas immunity arises during the process of phage invasion. If ε is the probability that the CRISPR/Cas immunity is successfully established in bacteria, then the transition rate of invaded bacteria to the resistance class is εkSP and the transition rate to the productively infected class is $(1 - \varepsilon)kSP$. Moreover, we let $k' = \kappa k$ denote the infection coefficient of resistant bacteria where

$0 < \kappa \leq 1$ describes the mutant probability of phage to escape CRISPR/Cas suppression. Finally, by incorporating the terms discussed above to describe the effects of CRISPR/Cas immunity into the model in [23], we arrive at the following model:

$$\begin{aligned}
\dot{R} &= D(R^0 - R) - f(R)(S + \mu M), \\
\dot{S} &= -DS + f(R)S - kSP, \\
\dot{M} &= -DM + \mu f(R)M + \varepsilon kSP - k'MP, \\
\dot{I} &= -DI + (1 - \varepsilon)kSP + k'MP - \delta I, \\
\dot{P} &= -DP - kSP - kMP + b\delta I,
\end{aligned} \tag{1}$$

where a dot denotes the differentiation with respect to time t; D and R^0 represent the dilution rate and nutrient supply concentration in the chemostat, respectively; $f(R)$ is the growth rate function which is taken to be Monod type: $f(R) = mR/(a + R)$, where m is the maximal growth rate and a is the half-saturation constant; parameter μ with $0 < \mu < 1$ is the cost of bacteria's resistance; parameter b represents the total number of free virus particles released by each productively infected cell over its lifespan; parameter δ is the death rate of infected bacteria.

The paper is organized as follows. In the next section we present the mathematical analysis of the model that include the stability and bifurcation of equilibria. Numerical simulations are provided in Section 3 to show the complicated dynamical behaviors of the model. A brief discussion concludes in Section 4. The proofs of a few theorems are given in Appendix.

2. Mathematical analysis.

In this section, we present the mathematical analysis for the stability and bifurcations of equilibria of (1). We start with the positivity and boundedness of solutions.

2.1. Positivity and boundedness of solutions.

Proposition 1. *All solutions of model* (1) *with nonnegative initial values are non-negative. In particular, a solution* $(R(t), S(t), M(t), I(t), P(t))$ *of model* (1) *is positive for* $t > 0$ *in the existence interval of the solution if* $R(0) > 0, S(0) > 0, M(0) > 0, I(0) > 0, P(0) > 0.$

Proof. We examine only the last conclusion of the proposition. First, we claim that $R(t)$ is positive for all $t > 0$ in the existence interval of the solution. Suppose not. Then there is a time $t_1 > 0$ such that $R(t_1) = 0$ and $R(t) > 0$ for $t \in (0, t_1)$. Since $R(t_1) = 0$, we have $\dot{R}(t_1) = DR^0 > 0$. Thus, there is a sufficiently small $\varepsilon > 0$ such that $R(t) < 0$ for all $t \in (t_1 - \varepsilon, t_1)$, which is a contradiction. Hence, $R(t)$ is positive for $t > 0$. It is evident that

$$S(t) = S(0)e^{\int_0^t [-D - kP(\theta) + f(R(\theta))]d\theta} > 0.$$

In a similar way we can show the positivity of $M(t), I(t)$ and $P(t)$. $\qquad \square$

Proposition 2. *All nonnegative solutions of model* (1) *are ultimately bounded.*

Proof. Set

$$L(t) = R(t) + S(t) + M(t) + I(t) + \frac{1}{b}P(t).$$

Calculating the derivative of L along the solution of (1), we obtain

$$\dot{L}(t) = DR^0 - DR(t) - DS(t) - DM(t) - DI(t) - \frac{1}{b}DP(t)$$

$$- \frac{1}{b}kS(t)P(t) - \frac{1}{b}kM(t)P(t)$$

$$\leq DR^0 - DL(t).$$

It follows that the nonnegative solutions of (1) exist on $[0, \infty)$ and

$$\limsup_{t \to \infty} L(t) \leq R^0. \tag{2}$$

Therefore, the nonnegative solutions of model (1) are ultimately bounded.   □

2.2. **Infection-free equilibria.** $E_0 = (R^0, 0, 0, 0, 0)$ is a trivial equilibrium. To find others, we assume

$$m > D, \quad f(R^0) > D. \tag{3}$$

Then $E_1 = (\lambda_1, R^0 - \lambda_1, 0, 0, 0)$ is an infection-free equilibrium, where $\lambda_1 = Da/(m - D)$. Similarly, $E_2 = (\lambda_2, 0, R^0 - \lambda_2, 0, 0)$ is an infection-free equilibrium where $\lambda_2 = Da/(\mu m - D)$ if

$$\mu m > D, \quad \mu f(R^0) > D. \tag{4}$$

It is easy to see that (3) and (4) imply

$$\lambda_1 < \mu \lambda_2 < \lambda_2.$$

Thus, the competitive exclusion in the absence of phage infection holds [24], and the boundary equilibrium E_2 is unstable. In what follows, we always assume that (3) and (4) are available.

The basic reproduction number R_0 of phage in the population of sensitive bacteria is computed through the matrix F of new infection and the infective transition matrix V:

$$F = \begin{pmatrix} 0 & (1 - \varepsilon)k(R^0 - \lambda_1) \\ 0 & 0 \end{pmatrix},$$

and

$$V = \begin{pmatrix} D + \delta & 0 \\ -b\delta & D + k(R^0 - \lambda_1) \end{pmatrix},$$

and is defined as the spectral radius of FV^{-1} [16]. Hence,

$$R_0 = \sqrt{\frac{b\delta(1 - \varepsilon)k(R^0 - \lambda_1)}{(D + \delta)[D + k(R^0 - \lambda_1)]}}.$$

Analogously, the basic reproduction number R_0^M of phage in the population of resistant bacteria is

$$R_0^M = \sqrt{\frac{b\delta\kappa(R^0 - \lambda_2)}{(D + \delta)[D + k(R^0 - \lambda_2)]}}.$$

Theorem 2.1. *The infection-free equilibrium E_1 is locally asymptotically stable if $R_0 < 1$ and unstable if $R_0 > 1$.*

The proof of Theorem 2.1 is postponed to Appendix.

Theorem 2.2. *The infection-free equilibrium E_1 is globally asymptotically stable if $bk(R^0 - \lambda_1)/D < 1$.*

Proof. Define a Lyapunov function by

$$V(t) = R(t) - R_1 - \int_{R_1}^{R} \frac{f(R_1)}{f(\xi)} d\xi + S(t) - S_1 - S_1 \ln \frac{S}{S_1} + M(t) + I(t) + \frac{1}{b}P(t),$$

where $R_1 = \lambda_1$ and $S_1 = R^0 - \lambda_1$. Calculating the derivative of V along the solution of (1), we obtain

$$\dot{V}(t) = \left(1 - \frac{f(R_1)}{f(R)}\right)\dot{R}(t) + (1 - \frac{S_1}{S})\dot{S}(t) + \dot{M}(t) + \dot{I}(t) + \frac{1}{b}\dot{P}(t)$$

$$= D(R^0 - R) - \frac{D(R^0 - R)f(R_1)}{f(R)} + (S + \mu M)f(R_1) + (D + kP - f(R))S_1$$

$$- DS - DM - DI - \frac{D}{b}P - \frac{kSP + kMP}{b}$$

$$= D(R^0 - R_1)(2 - \frac{f(R_1)}{f(R)} - \frac{f(R)}{f(R_1)}) - D(R - R_1)(1 - \frac{f(R_1)}{f(R)}) - D(1 - \mu)M$$

$$- DI + (kS_1 - \frac{D}{b})P - \frac{kSP + kMP}{b}.$$

Since $bk(R^0 - \lambda_1)/D < 1$, it follows that $\dot{V} \le 0$. Set

$$D_0 = \{(R, S, M, I, P) \mid \dot{V} = 0\}.$$

It is easy to examine that the largest invariant set in D_0 is

$$\{(R, S, M, I, P) \mid R = \lambda_1, S = S_1, M = 0, I = 0, P = 0\}.$$

It follow from the LaSalle's invariance principle [22] that E_1 is globally stable. □

2.3. **Infection equilibria.** In this subsection, we consider the infection equilibria of system (1) which satisfy

$$D(R^0 - R) - f(R)S - \mu f(R)M = 0,$$
$$- DS + f(R)S - kSP = 0,$$
$$- DM + \mu f(R)M + \varepsilon kSP - k'MP = 0, \qquad (5)$$
$$- DI + (1 - \varepsilon)kSP + k'MP - \delta I = 0,$$
$$- DP - kSP - kMP + b\delta I = 0.$$

If $E_3 = (R_3, 0, M_3, I_3, P_3)$ is an infection equilibrium dominated by the resistance strain, we have

$$D(R^0 - R_3) - \mu f(R_3)M_3 = 0,$$
$$- DM_3 + \mu f(R_3)M_3 - k'M_3P_3 = 0,$$
$$- DI_3 + k'M_3P_3 - \delta I_3 = 0,$$
$$- DP_3 - kM_3P_3 + b\delta I_3 = 0.$$

It follows that

$$P_3 = \frac{\mu f(R_3) - D}{k'}, \quad M_3 = \frac{D(R^0 - R_3)}{\mu f(R_3)}, \quad I_3 = \frac{k'M_3P_3}{D + \delta},$$

and R_3 satisfies

$$- DP_3 - kM_3P_3 + b\delta I_3 = P_3(kA_2M_3 - D) = 0,$$

where $A_2 = b\delta\kappa/(D+\delta) - 1$. Substituting $M_3 = D(R^0 - R_3)/\mu f(R_3)$ and $f(R_3) = mR_3/(a + R_3)$ into it, we get

$$g(R_3) := R_3^2 + (a + mA - R^0)R_3 - R^0 a = 0, \tag{6}$$

where

$$A = \frac{\mu}{k} \frac{D+\delta}{b\delta\kappa - (D+\delta)}.$$

By direct calculations, we obtain

$$g(R^0) = mAR^0 > 0,$$

$$g(\lambda_2) = (\lambda_2 - R^0)(\lambda_2 + a) + mA\lambda_2.$$

Since $\mu f(R_2) > D = \mu f(\lambda_2)$, we have $\lambda_2 < R_2$. Clearly, $g(\lambda_2) < 0$ if

$$A < \frac{(R^0 - \lambda_2)(\lambda_2 + a)}{m\lambda_2} = \frac{\mu(R^0 - \lambda_2)}{D},$$

which is equivalent to $R_0^M > 1$. Consequently, there exists a unique infection equilibrium E_3 when $R_0^M > 1$, where R_3 lies between λ_2 and R^0, and E_3 does not exist when $R_0^M < 1$. As a result, we can state the following theorem for the existence of E_3.

Theorem 2.3. *The infection equilibrium E_3 exists if $R_0^M > 1$ and does not exist if $R_0^M < 1$.*

To study the local stability of infection equilibria E_3, we set

$$\begin{aligned}
a_1 =& kM_3 + 3D + \delta + \mu M_3 f^{'}(R_3), \\
a_2 =& kM_3(\mu M_3 f^{'}(R_3) + 2D - \mu f(R_3)) \\
& + D(2D + \delta) + (2D + \delta + \mu f(R_3))\mu M_3 f^{'}(R_3), \\
a_3 =& DkM_3(\mu M_3 f^{'}(R_3) + D - \mu f(R_3)) + D(D + \delta)(\mu f(R_3) - D) \\
& + \mu f(R_3)\mu M_3 f^{'}(R_3)(2D + \delta), \\
a_4 =& kA_2(D + \delta)(\mu M_3 f^{'}(R_3) + D)(\mu f(R_3) - D).
\end{aligned} \tag{7}$$

Moreover, for $\kappa < \mu$, we define

$$\lambda_3 = f^{-1}(D(1 - \kappa)/(\mu - \kappa)). \tag{8}$$

Theorem 2.4. *The infection-resistant equilibrium E_3 is asymptotically stable if*

$$\kappa < \mu, \quad R_3 > \lambda_3, \quad a_1 a_2 > a_3, \quad (a_1 a_2 - a_3)a_3 - a_4 a_1^2 > 0, \tag{9}$$

and is unstable when $\kappa > \mu$, or

$$\kappa < \mu, \quad R_3 < \lambda_3, \quad a_1 a_2 > a_3, \quad (a_1 a_2 - a_3)a_3 - a_4 a_1^2 > 0. \tag{10}$$

The proof of Theorem 2.4 is given in Appendix.

Let us now consider the existence of coexistence equilibrium of (1). Denote such an equilibrium by $E_4 = (R_4, S_4, M_4, I_4, P_4)$. By (5) we have

$$P_4 = \frac{f(R_4) - D}{k},$$

$$M_4 = \frac{\varepsilon D(R^0 - R_4)(f(R_4) - D)}{[D - \mu f(R_4) + \mu\varepsilon(f(R_4) - D) + k'P_4]f(R_4)},$$

$$S_4 = \frac{D(R^0 - R_4)[k'P_4 + D - \mu f(R_4)]}{[D - \mu f(R_4) + \mu\varepsilon(f(R_4) - D) + k'P_4]f(R_4)}, \tag{11}$$

$$I_4 = \frac{[(1 - \varepsilon)kS_4 + k'M_4]P_4}{D + \delta}.$$

Since $P_4 > 0, S_4 > 0, I_4 > 0$ and $M_4 > 0$, we need

$$f(R_4) > D, \quad k'P_4 + D - \mu f(R_4) > 0. \tag{12}$$

Note that

$$F(R_4) := k'P_4 + D - \mu f(R_4) = D(1 - \kappa) + (\kappa - \mu)f(R_4),$$

where $\kappa = k'/k$ is the phage mutant rate and the value of κ can represents the relative resistance of bacteria for the CRISPR/Cas immune system. Though there is no definite relation between κ and μ in biology, which is presented as fluctuating selection dynamics [7], in this paper we simply consider two ways for the CRISPR/Cas immune efficiency. First, we assume $\kappa \geq \mu$, which means that the mutant rate is great than the cost of bacteria's resistance. Secondly, we consider $\kappa < \mu$, which means that the mutant rate is inferior to the cost of bacteria's resistance.

Note that R_4 is the positive solution of the following equation:

$$-D + \left(\frac{b\delta\kappa}{D + \delta} - 1\right)kM_4 + \left(b\delta\frac{1 - \varepsilon}{D + \delta} - 1\right)kS_4 = 0. \tag{13}$$

Set

$$A_1 = b\delta(1 - \varepsilon)/(D + \delta) - 1, \quad A_2 = b\delta\kappa/(D + \delta) - 1. \tag{14}$$

Using (11) and $f(R_4) = mR_4/(a + R_4)$, we see that (13) holds if and only if

$$G(R_4) := k(R^0 - R_4)\left(e_1 + e_2\frac{D}{f(R_4)}\right) - (e_3f(R_4) + e_4) = 0,$$

where

$$e_1 = \kappa A_1 - \mu A_1 + \varepsilon A_2, \quad e_2 = A_1 - \kappa A_1 - \varepsilon A_2,$$
$$e_3 = \mu\varepsilon - \mu + \kappa, \quad\quad\quad e_4 = (1 - \mu\varepsilon - \kappa)D.$$

Let $g_1(R_4) = k(R^0 - R_4)(e_1 + e_2D/f(R_4))$ and $g_2(R_4) = e_3f(R_4) + e_4$. It is easy to see that there are at most two intersection points for these two curves.

Evidently, $G(R^0) = -D < 0$. When $R_4 = \lambda_2$, we get $S_4 = 0$ and $M_4 = R^0 - \lambda_2$. As a result, we have

$$G(\lambda_2) = -D + kA_2(R^0 - \lambda_2) = (D + k(R^0 - \lambda_2))(R^M - 1).$$

Thus, $G(\lambda_2) > 0$ if and only if $R_0^M > 1$, where R^M is the square of the basic reproduction number R_0^M. Similarly, we get

$$G(\lambda_1) = -D + kA_1(R^0 - \lambda_1) = (D + k(R^0 - \lambda_1))(R_0^2 - 1).$$

Hence, $G(\lambda_1) > 0$ if and only if $R_0 > 1$. From the above arguments, we conclude that system (1) has a unique positive equilibrium E_4^{**} between λ_2 and R^0 when $R_0 > 1$ and $R_0^M > 1$, has a unique positive equilibrium E_4^* between λ_1 and λ_2 when $R_0 > 1$ and $R_0^M < 1$, admits two positive equilibria E_4^{**} and E_4^* if $R_0 < 1$ and $R_0^M > 1$, and has no positive equilibrium if $R_0 < 1$ and $R_0^M < 1$.

For the case where $\kappa \geq \mu$, $F(R_4)$ are always positive. But for the case where $\kappa < \mu$, $F(R_4)$ may be negative at the equilibrium E_4^{**}. In view of the definition of λ_3 in (8), we see $F(\lambda_3) = 0$. If $\lambda_3 < R^0$, we have

$$G(\lambda_3) = D(R^0 - \lambda_3)(e_1 + e_2 \frac{D}{f(\lambda_3)}) - (e_3 f(\lambda_3) + e_4)$$

$$= D(R^0 - \lambda_3)\frac{\varepsilon A_2(1 - \mu)}{1 - \kappa} - \frac{\mu \varepsilon D(1 - \mu)}{\mu - \kappa}.$$

Since $1 - \kappa > \mu(\mu - \kappa)$, we see that $\lambda_3 > \lambda_2$ and positive equilibrium E_4^{**} exists when $G(\lambda_3) \leq 0$, and does not exist when $G(\lambda_3) > 0$. It is easy to examine that $G(\lambda_3) \leq 0$ is equivalent to

$$\lambda_3 \geq R^0 - \frac{\mu(1 - \kappa)}{A_2(\mu - \kappa)}, \tag{15}$$

and $G(\lambda_3) > 0$ is equivalent to

$$\lambda_3 < R^0 - \frac{\mu(1 - \kappa)}{A_2(\mu - \kappa)}. \tag{16}$$

Solve $G(\lambda_3) = 0$ in b to obtain

$$b^* = \frac{D + \delta}{\delta} \left(\frac{(\mu - \kappa)(R^0 - \lambda_3)}{(1 - \kappa)\mu} + 1 \right).$$

Notice that A_2 increases as b increases. Thus, E_4^{**} does not exist as b increases from b^*. In view of $F(\lambda_3) = 0$, it follows that when $b = b^*$, we have $R_4 = \lambda_3, S_4 = 0$ and

$$P_4 = \frac{f(\lambda_3) - D}{k} = \frac{D(1 - \kappa)}{k(\mu - \kappa)},$$

$$M_4 = \frac{D(R^0 - \lambda_3)(f(\lambda_3) - D)}{\mu f(\lambda_3)},$$

$$I_4 = \frac{k' M_4 P_4}{D + \delta}.$$

Set

$$R^* := \frac{R_0}{R_0^M} = \sqrt{\frac{(D + k(R^0 - \lambda_2))(1 - \varepsilon)(R^0 - \lambda_1)}{\kappa(R^0 - \lambda_2)(D + k(R^0 - \lambda_1))}}.$$

Solving $R^* = 1$ in ε, we get

$$\varepsilon = \varepsilon^* := 1 - \frac{\kappa(R^0 - \lambda_2)(D + k(R^0 - \lambda_1))}{(D + k(R^0 - \lambda_2))(R^0 - \lambda_1)}.$$

Thus, $\varepsilon > \varepsilon^*(< \varepsilon^*)$ is equivalent to $R^* < 1(> 1)$.

Let us consider three cases:

(C1) $\kappa \geq \mu$, or $\kappa < \mu$ and $\lambda_3 \geq R^0$.

(C2) $\kappa < \mu$ and $b \leq b^*$ hold for $\lambda_3 < R^0$.

(C3) $\kappa < \mu$ and $b > b^*$ hold for $\lambda_3 < R^0$.

The following Theorem states the existence of infection equilibria of (1) according to the above discussions.

Theorem 2.5. *Let (C1) or (C2) hold. Then for $\varepsilon > \varepsilon^*$, we have:*

(i) If $0 < R_0 < R^*$, there is no infection equilibrium.

(ii) If $R_0 = R^*$, there exists one coexistence equilibrium E_4^* of multiplicity 2.

(iii) If $R^* < R_0 < 1$, there exist two coexistence equilibria E_4^* and E_4^{**}.

(iv) If $1 < R_0$, there is only one coexistence equilibrium E_4^{**}.

For $\varepsilon < \varepsilon^*$ we have:

(i) If $0 < R_0 < 1$, there is no infection equilibrium.

(ii) If $1 < R_0 < R^*$, there is only one coexistence equilibrium E_4^*.

(iii) If $R^* < R_0$, there is only one positive equilibrium E_4^{**}.

Proof. Note that $R_0 = R_0^M$ when $\varepsilon = \varepsilon^*$, and the condition $\varepsilon > \varepsilon^*(< \varepsilon^*)$ is equivalent to $R_0 < R_0^M(> R_0^M)$. Furthermore, $0 < R_0 < R^*$ with $\varepsilon > \varepsilon^*$ is equivalent to $R_0 < R_0^M < 1$, $R^* < R_0 < 1$ is equivalent to $R_0 < 1 < R_0^M$, and $R_0 > 1$ with $\varepsilon > \varepsilon^*$ is equivalent to $1 < R_0 < R_0^M$. For $\varepsilon < \varepsilon^*$, $0 < R_0 < 1$ implies $R_0^M < R_0 < 1$, $1 < R_0 < R^*$ implies $R_0^M < 1 < R_0$, and $R_0 > R^*$ implies $1 < R_0^M < R_0$. Obviously, $F(R_4) > 0$ always holds in case $(C1)$ or case $(C2)$. The conclusions of this theorem follow immediately from the preceding discussions. □

This theorem indicates that the system (1) exhibits a backward bifurcation as R_0 crosses unity when $\varepsilon > \varepsilon^*$ for case $(C1)$ or case $(C2)$. Moreover, it admits a forward bifurcation when $\varepsilon < \varepsilon^*$.

Notice that the equilibrium E_4^{**} does not exist for case $(C3)$. We can present another theorem for the existence of infection equilibria.

Theorem 2.6. *Let $(C3)$ hold. The existence of infection equilibria is given as follows:*

For $\varepsilon > \varepsilon^*$, we have

(i) *If $0 < R_0 < R^*$, there is no infection equilibrium;*

(ii) *If $R^* < R_0 < 1$, there are two infection equilibria E_4^* and E_3;*

(iii) *If $R_0 > 1$, there is only one infection equilibrium E_3.*

For $\varepsilon < \varepsilon^*$, we have

(i) *If $0 < R_0 < 1$, there is no infection equilibrium;*

(ii) *If $1 < R_0 < R^*$, there exists one infection equilibrium E_4^*;*

(iii) *If $R_0 > R^*$, there is only one infection equilibrium E_3.*

The proof of this Theorem is omitted because it is similar to it for Theorem 2.5.

Theorem 2.6 presents the conditions for a forward bifurcation of the infection-free equilibrium and a transcritical bifurcation of the coexist equilibrium. Note that for $\lambda_3 \geq R^0$, there is a backward bifurcation as R_0 crosses unity, but for $\lambda_3 < R^0$, the existence of a backward bifurcation depends on the relation between κ and μ. More specifically, if $\kappa \geq \mu$, the backward bifurcation always exists and is independent of the size of b. But for $\kappa < \mu$, a critical value b^* is needed to ensure the existence of backward bifurcation.

2.4. **Global analysis for full CRISPR/Cas immunity.** We now explore the persistence and extinction of phages in the case where $\kappa = 0$, which leads to $k' = 0$ and means that CRISPR/Cas immunity can fully suppress the invaded phages.

Theorem 2.7. *Let $k' = 0$. Then we have the following conclusions:*

(i) *The positive solutions of (1) satisfy*

$$\lim_{t \to \infty} (R(t), S(t), M(t), I(t), P(t)) = (\lambda_1, R^0 - \lambda_1, 0, 0, 0)$$

if $R_0 < 1$.

(ii) *If $R_0 > 1$, then bacteria populations and phage infection are uniformly persistent, i.e., there is a positive constant η such that each positive solution of (1)*

satisfies

$$\liminf_{t\to\infty} S(t) > \eta, \ \ \liminf_{t\to\infty} M(t) > \eta, \ \ \liminf_{t\to\infty} I(t) > \eta, \ \ \liminf_{t\to\infty} P(t) > \eta.$$

Proof. (i) For a continuous function $f(t)$ which is bounded on $[0, \infty)$, we set

$$f^\infty = \limsup_{t\to\infty} f(t), \ \ f_\infty = \liminf_{t\to\infty} f(t).$$

First, we claim that a positive solution of (1) admits $S^\infty \leq R^0 - \lambda_1$. Indeed, by (2) we get

$$\dot{S} \leq -DS + f(R)S \leq -DS + f(R^0 + \eta_0 - S)S, \ \text{ for all large } t,$$

where $\eta_0 > 0$ is sufficiently small. Then by similar arguments to those in [42], we obtain $S^\infty \leq R^0 - \lambda_1 + \eta_0$. Taking $\eta_0 \to 0$ leads to the conclusion as claimed. As a result of the claim, we see from the last two equations of (1) that for all large t:

$$\begin{aligned}
\dot{I} &\leq -DI + (1-\varepsilon)k(R^0 - \lambda_1 + \eta_1)P - \delta I, \\
\dot{P} &\leq -DP - k(R^0 - \lambda_1 - \eta_1)P + b\delta I,
\end{aligned} \tag{17}$$

where $\eta_1 > 0$ is sufficiently small. Let us consider a comparison system:

$$\begin{aligned}
\dot{I} &= -DI + (1-\varepsilon)k(R^0 - \lambda_1 + \eta_1)P - \delta I, \\
\dot{P} &= -DP - k(R^0 - \lambda_1 - \eta_1)P + b\delta I.
\end{aligned} \tag{18}$$

The Jacobian matrix of (18) is

$$J_1 := \begin{pmatrix} -(D+\delta) & (1-\varepsilon)k(R^0 - \lambda_1 + \eta_1) \\ b\delta & -(D + k(R^0 - \lambda_1 - \eta_1)) \end{pmatrix}.$$

Since $R_0 < 1$, it is easy to examine that the eigenvalues of J_1 have negative real part for small $\eta_1 > 0$. Thus, the positive solutions of (18) approach to $(0,0)$ as $t \to \infty$. It follows from (17) and the comparison principle that a positive solution of (1) exhibits that $(I(t), P(t)) \to (0,0)$ as $t \to \infty$. As a consequence, by the theory of an asymptotically autonomous system [43], it suffices to consider the asymptotic behaviors of the limiting system:

$$\begin{aligned}
\dot{R} &= D(R^0 - R) - f(R)(S + \mu M), \\
\dot{S} &= -DS + f(R)S, \\
\dot{M} &= -DM + \mu f(R)M.
\end{aligned} \tag{19}$$

Since $\lambda_1 < \lambda_2$, it follows from [24, 25] that the positive solution of (1) exhibits that $(R(t), S(t), M(t)) \to (\lambda_1, R^0 - \lambda_1, 0)$ as $t \to \infty$.

(ii) We first show that phage infection is uniformly persistent if $R_0 > 1$. Set

$$\begin{aligned}
X &= \{(R, S, M, I, P) : R \geq 0, S \geq 0, M \geq 0, I \geq 0, P \geq 0\}, \\
X_0 &= \{(R, S, M, I, P) \in X : I > 0, P > 0\}, \\
\partial X_0 &= X \setminus X_0.
\end{aligned}$$

We wish to show that (1) is uniformly persistent with respect to $(X_0, \partial X_0)$.

By Proposition 1, we see that both X and X_0 are positively invariant for model (1). Evidently, ∂X_0 is relatively closed in X. Moreover, Proposition 2 indicates that the nonnegative solutions of model (1) are point dissipative. Then we denote by J_∂ the largest positively invariant set of (1) in ∂X_0. By similar discussions to those in [46], we see

$$J_\partial = \{(R, S, M, I, P) \in X : I = 0, P = 0\}.$$

It is clear that there are three equilibria E_0, E_1 and E_2 in J_∂. Since $\lambda_1 < \lambda_2$, by [24,25] we see that E_1 is asymptotically stable in J_∂ and the nonnegative solutions of (1) in J_∂ except for E_0 and E_2 tend to E_1 as $t \to \infty$. Therefore, E_0, E_1 and E_2 are isolated invariant sets in J_∂ and no subset of $\{E_0, E_1, E_2\}$ forms a cycle in J_∂.

Note that (3) and (4) imply that a positive solution of (1) cannot approach E_0 as $t \to \infty$. We claim that this is also the case for E_1. Suppose not. Then there is a positive solution of (1) that satisfies $(R(t), S(t), M(t), I(t), P(t)) \to (\lambda_1, R^0 - \lambda_1, 0, 0, 0)$ as $t \to \infty$. It follows that for all large t, we have

$$
\begin{aligned}
\dot{I} &\geq -DI + (1 - \varepsilon)k(R^0 - \lambda_1 - \eta_2)P - \delta I, \\
\dot{P} &\geq -DP - k(R^0 - \lambda_1 + \eta_2)P + b\delta I,
\end{aligned}
\tag{20}
$$

where $\eta_2 > 0$ is sufficiently small. Let

$$
J_2 := \begin{pmatrix} -(D + \delta) & (1 - \varepsilon)k(R^0 - \lambda_1 - \eta_2) \\ b\delta & -(D + k(R^0 - \lambda_1 + \eta_2)) \end{pmatrix}.
$$

Since $R_0 > 1$, it is easy to examine that J_2 has a positive eigenvalue with a positive eigenvector for small $\eta_2 > 0$. It follows that the positive solutions of the following comparison system

$$
\begin{aligned}
\dot{I} &= -DI + (1 - \varepsilon)k(R^0 - \lambda_1 - \eta_2)P - \delta I, \\
\dot{P} &= -DP - k(R^0 - \lambda_1 + \eta_2)P + b\delta I
\end{aligned}
\tag{21}
$$

tend to infinity as $t \to \infty$. As a result, by (20) and the comparison principle we see that the positive solution of (1) satisfies $(I(t), P(t)) \to (\infty, \infty)$ as $\to \infty$. We are led to a contradiction. Consequently, there is no positive solution of (1) that approaches E_1 as $t \to \infty$. In a similar way, we conclude that there is no positive solution of (1) that approaches E_2 as $t \to \infty$. Hence, $W^s(E_i) \cap X_0 = \emptyset, i = 0, 1, 2$. Finally, we claim that E_0, E_1 and E_2 are also isolated in X_0. Indeed, if E_1 is not isolated, then there exists a positive solution of (1) which is so close to E_1 for all time that (20) holds. Then repeating the above arguments leads to a contradiction. Similar discussions apply also to E_0 and E_2. Consequently, we conclude from [44,48] that phage infection is uniformly persistent.

By adopting the same techniques as above, we can show that the population S of sensitive bacteria is uniformly persistent. From the third equation and (2), we obtain

$$
\dot{M} \geq -DM + \varepsilon kSP.
$$

This, together with the uniform persistence of population S and population P, implies that the population M is uniformly persistent. □

3. **Numerical simulation.** In this section, we implement numerical simulations to illustrate the theoretical results and explore more interesting solution patterns of model (1). Take the same parameter values as those in [23] where $D = 0.2$, $m = 0.7726$, $R^0 = 0.178212$, $a = 0.0727$ and $k' = 0.15$, $\delta = 0.4$. Then we choose $\mu = 0.9$ so that $\mu f(R^0) > D$. First, we consider the case where $\kappa \geq \mu$. Let $k = 0.15$ which means $\kappa = 1 > 0.9 = \mu$. If $\varepsilon = 0.8 > \varepsilon^* = 0.023314$, there is a backward bifurcation, which is shown in panel (b) of Fig. 1. Furthermore, if $\varepsilon = 0.01 < \varepsilon^* = 0.023314$, there is a forward bifurcation, which is shown in panel (a) of Fig. 1.

To demonstrate the second case where $\kappa < \mu$, we select $\mu = 0.8$, $k = 0.15$, $\kappa = 0.6666$ and $b = 110 \leq b^* = 135.618$. Then $(C2)$ holds. For $\varepsilon = 0.3 < \varepsilon^* = 0.370362$,

FIGURE 1. Bifurcation graphs for $\kappa \geq \mu$ in case $(C1)$. Panel (a) shows the forward bifurcation with $\varepsilon = 0.01$. Panel (b) indicates the backward bifurcation with $\varepsilon = 0.8$. H denotes a Hopf bifurcation point, LP means a fold bifurcation point and BP represents the branch point E_1.


FIGURE 2. Bifurcation graphs for case $(C2)$. Panel (a) shows the forward bifurcation with $\varepsilon = 0.3$ and panel (b) demonstrates the backward bifurcation with $\varepsilon = 0.8$. H denotes a Hopf bifurcation point, LP means a fold bifurcation point and BP represents a branch point. The solid lines represent stable branches and dashed lines mean unstable branches.

a forward bifurcation occurs, which is shown in panel (a) of Fig.2. For $\varepsilon = 0.8 > \varepsilon^*$, we get a backward bifurcation shown in panel (b) of Fig.2.

To show the case $(C3)$, we let $k = 0.15, \kappa = 0.8$, $b^* = 46.802, \varepsilon^* = 0.218651$ and $b = 110 > b^*$. Then $(C3)$ holds. For $\varepsilon = 0.1 < \varepsilon^*$, a transcritical bifurcation occurs at E_4 and a forward bifurcation emerges at E_1, which are shown in panel (a) of Fig.3. For $\varepsilon = 0.8 > \varepsilon^*$, there are a backward bifurcation from E_1 and a transcritical bifurcation at E_3, which are shown in Fig.3.

With the help of MatCont package [15], we obtain more information for the dynamical behaviors of system (1), where the behaviors for $\kappa < \mu$ is more complicated than those for $\kappa \geq \mu$ when ε and R_0 vary. As shown in Fig.2 where case $(C2)$ holds, the coexistence equilibrium E_4 undergoes a Hopf bifurcation and

(a)   (b)

FIGURE 3. Bifurcation graphs for case $(C3)$. Panel (a) shows the forward bifurcation at E_1 and a transcritical bifurcation at E_3 when $\varepsilon = 0.1$ and panel (b) demonstrates the bistable phenomena between E_1, E_3 and a transcritical bifurcation at E_4 when $\varepsilon = 0.8$. H denotes a Hopf bifurcation point, LP means a fold bifurcation point and BP represents a branch point. The solid lines represent stable branches and dashed lines mean unstable branches.

a fold bifurcation. More specifically, the Hopf bifurcation point (H) occurs with $R_0 = 1.277977$, and a fold bifurcation point (LP) appears with $R_0 = 0.792644$. At the Hopf bifurcation point (H), the first Lyapunov coefficient is -5.079166×10^{-2}, which means that the Hopf bifurcation is supercritical and the periodic solutions are born stable. The fold bifurcation leads to the existence of multiple infection equilibria with $0.792644 < R_0 < 1$. Note that the simulation results indicate that the larger CRISPR/Cas immune efficiency ε can induce backward bifurcations, which supports the results of our theoretical analysis.

(a)   (b)

FIGURE 4. Graphs of bistable behaviors in case $(C1)$ with $\kappa \geq \mu$. Panel (a) shows the bistability of the infection-free equilibrium and an coexist equilibrium where $\varepsilon = 0.01$, $b = 130$. Panel (b) indicates the bistable coexistence of the infection-free equilibria with a stable periodic solution where $\varepsilon = 0.9$, $b = 260$.

As discussed above, a bistable coexistence between the infection-free equilibrium and an infection equilibrium may occur when $\varepsilon > \varepsilon^*$. Panel (a) of Fig.4 shows such

a phenomenon. Interestingly, we find the bistable coexistence of the infection-free equilibria with a stable periodic solution, which is shown in panel (b) of Fig.4.

4. **Discussions.** In this paper, we have developed a bacteriophage mathematical model based on CRISPR/Cas immune system. By combining theoretical analysis and numerical simulations, we have found that the model exhibits some new dynamical behaviors than the model without the immune responses in [23]. More specifically, the introduction of the CRISPR/Cas immune system induces a backward bifurcation from the infection-free equilibrium or a transcritical bifurcation from the coexist equilibrium, which means that although the basic infection reproduction number is below unity, the phage could coexist with bacteria. The coexistence of a stable infection-free equilibrium with a stable infection equilibrium(or stable coexist equilibrium), the bistable phenomenon of a stable infection-free equilibrium and a stable periodic solution are found, which are shown in panel (a) of Fig. 4 and panel (b) of Fig. 4. They provide reasonable explanations for the complexity of phage therapy [9, 29] or bacteria-phages coevolution [13], and the coexistence of bacteria with phage in the biological experiments [20, 29]. In contrast, there is no the backward bifurcation or bistable phenomena in the models of previous studies [23, 42] where the immune response is ignored.

For case ($C3$), the strain of sensitive bacteria may almost translated to resistent bacteria when the phage mutant rate (means as relative resistance) is inferior to the cost of bacteria's resistance for every values of ε, that is said, the CRISPR/Cas system have uninfluence on the bacteria and phages coexistence or the bacteria's diversity, which only influence by the released virus particles b in this case. This analysis is consistent with [27]. The value of b^* increases when μ increases or κ decreases, while the effective of μ is greatly less than the change of κ. Thus, decreasing the values of phage mutant rate is contributed to sensitive bacteria survival when resistant bacteria have great bacteria's resistance cost value.

The mathematical analysis for the stability and bifurcation of equilibria of (1) in this paper present some insights into the underlying phage infection mechanisms by considering the CRISPR/Cas system in bacteria. It will be interesting to consider the analytical conditions for the Hopf bifurcation and the homoclinic bifurcation of the model and reveal how the immune response affect these bifurcations. It will be also interesting to consider the effect of latent period of infection like it in [23] or the nonlinear death rates like those in [29]. We leave these as future researches.

Appendix. *Proof Theorem 2.1.* Let $S_1 = R^0 - \lambda_1$. Evaluating the Jacobian matrix of system (1) at E_1 gives

$$J(E_1) = \begin{pmatrix} -D - S_1 f'(\lambda_1) & -D & -\mu D & 0 & 0 \\ S_1 f'(\lambda_1) & 0 & 0 & 0 & -kS_1 \\ 0 & 0 & -D + \mu D & 0 & \varepsilon k S_1 \\ 0 & 0 & 0 & -D - \delta & (1-\varepsilon)kS_1 \\ 0 & 0 & 0 & b\delta & -D - kS_1 \end{pmatrix},$$

where f' denotes the differentiation of function f. The characteristic equation of $J(E_1)$ in ω is

$$(\omega + D)(\omega + S_1 f^{'}(\lambda_1))[\omega^2 + (2D + \delta + kS_1)\omega + f_0](\omega + D(1 - \mu)) = 0, \quad \text{(A-1)}$$

where

$$f_0 = (D + kS_1)(D + \delta)(1 - R_0^2).$$

Since $0 < \mu < 1$, it is easy to see that all the roots of characteristic equation (A-1) have negative real parts if $R_0 < 1$, and the characteristic equation has one positive root if $R_0 > 1$. It follows from the Routh-Hurwitz criterion that E_1 is locally asymptotically stable. This completes the proof. $\qquad\square$

Proof Theorem 2.4. Evaluating the Jacobian of (1) at E_3 gives

$$J(E_3) = \begin{pmatrix} -D - \mu M_3 f^{'}(R_3) & -f(R_3) & -\mu f(R_3) & 0 & 0 \\ 0 & -D + f(R_3) - kP_3 & 0 & 0 & 0 \\ \mu M_3 f^{'}(R_3) & \varepsilon kP_3 & 0 & 0 & -k' M_3 \\ 0 & (1 - \varepsilon)kP_3 & k'P_3 & -D - \delta & k' M_3 \\ 0 & -kP_3 & -kP_3 & b\delta & -D - kM_3 \end{pmatrix}.$$

Using $k'M_3(D + \delta - b\delta) = -D(D + \delta)$ and $k'P_3 = \mu f(R_3) - D$, we get the characteristic equation in ω:

$$(\omega - f(R_3) + kP_3 + D)(\omega^4 + a_1\omega^3 + a_2\omega^2 + a_3\omega + a_4) = 0,$$

where a_i (i=1,2,3,4) are defined by (7). Set

$$F_1(\omega) = \omega - f(R_3) + kP_3 + D, \quad F_2(\omega) = \omega^4 + a_1\omega^3 + a_2\omega^2 + a_3\omega + a_4.$$

Note that $a_1 > 0$ and $a_4 > 0$. We see that the last two inequalities in (9) ensure that all the principal minors in the Routh-Hurwitz criteria are positive. Thus, the stability of E_3 is determined by the sign of $f(R_3) - kP_3 - D$. Using $k'P_3 = \mu f(R_3) - D$ and $f(R_3) = kA_2(R^0 - R_3)/\mu$, we get

$$f(R_3) - kP_3 - D = (1 - \frac{\mu}{\kappa})f(R_3) + (\frac{1}{\kappa} - 1)D := F_0(\omega).$$

It is easy to see $F_0(R_3)$ is positive for any value if $\kappa \geq \mu$, which leads to the instability of E_3. Furthermore, if $\kappa < \mu$, $F_0(R_3)$ is negative when

$$f(R_3) > \frac{D(1 - \kappa)}{\mu - \kappa},$$

which is equivalent to $R_3 > \lambda_3$. Consequently, E_3 is asymptotically stable if (9) holds, and is unstable if (10) is available. This completes the proof. $\qquad\square$

REFERENCES

[1] L. J. Allen and S. W. Vidurupola, Impact of variability in stochastic models of bacteria-phage dynamics applicable to phage therapy, *Stochastic Analysis and Applications*, **32** (2014), 427–449.

[2] I. Aviram and A. Rabinovitch, Bactria and lytic phage coexistence in a chemostat with periodic nutrient supply, *Bulletin of Mathematical Biology*, **76** (2014), 225–244.

[3] E. Beretta and Y. Kuang, Modeling and analysis of a marine bacteriophage infection, *Mathematical Biosciences*, **149** (1998), 57–76.

[4] E. Beretta and Y. Kuang, Modeling and analysis of a marine bacteriophage infection with latency period, *Nonlinear Analysis: Real World Applications*, **2** (2001), 35–74.

[5] B. J. Bohannan and R. E. Lenski, Linking genetic change to community evolution: Insights from studies of bacteria and bacteriophage, *Ecology Letters*, **3** (2000), 362–377.

[6] S. J. Brouns, M. M. Jore and M. Lundgren, Small CRISPR RNAs guide antiviral defense in prokaryotes, *Science*, **321** (2008), 960–964.

[7] A. Buckling and M. Brockhurst, Bacteria-virus coevolution, *Evolutionary Systems Biology*, **751** (2012), 347–370.

[8] J. J. Bull, C. S. Vegge and M. Schmerer, Phenotypic resistance and the dynamics of bacterial escape from phage control, *PloS One*, **9** (2014), e94690.

[9] B. J. Cairns, A. R. Timms and V. Jansen, Quantitative models of vitro bacteriophage-host dynamics and their application to phage therapy, *PLoS Pathog*, **5** (2009), e1000253.

[10] A. Calsina and J. J. Rivaud, A size structured model for bacteria-phages interaction, *Nonlinear Analysis: Real World Applications*, **15** (2014), 100–117.

[11] A. Campbell, Conditions for existence of bacteriophages, *Evolution*, **15** (1961), 153–165.

[12] C. L. Carrillo, R. J. Atterbury and A. El-Shibiny, Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens, *Applied and Environmental Microbiology*, **71** (2005), 6554–6563.

[13] J. J. Dennehy, What can phages tell us about host-pathogen coevolution?, *International Journal of Evolutionary Biology*, **2012** (2012), Article ID 396165, 12 pages.

[14] H. Deveau, J. E. Garneau and S. Moineau, CRISPR/Cas system and its role in phage-bacteria interactions, *Annual Review of Microbiology*, **64** (2010), 475–493.

[15] A. Dhooge, W. Govaerts and Y. A. Kuznetsov, MATCONT: A MATLAB package for numerical bifurcation analysis of ODEs, *ACM Trans Math Software*, **29** (2003), 141–164.

[16] P. van den Driessche and J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, *Math. Biosciences*, **180** (2002), 29–48.

[17] D. H. Duckworth, Who discovered bacteriophage?, *Bacteriological Reviews*, **40** (1976), 793–802.

[18] P. C. Fineran and E. Charpentier, Memory of viral infections by CRISPR-Cas adaptive immune systems: Acquisition of new information, *Virology*, **434** (2012), 202–209.

[19] J. E. Garneau and M. Dupuis, The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA, *Nature*, **468** (2010), 67–71.

[20] P. Gómez and A. Buckling, Bacteria-phage antagonistic coevolution in soil, *Science*, **332** (2011), 106–109.

[21] S. A. Gourley and Y. Kuang, A delay reaction-diffusion model of the spread of bacteriophage infection, *SIAM Journal of Applied Mathematics*, **65** (2004), 550–566.

[22] J. K. Hale and S. M. V. Lunel, *Introduction to Functional Differential Equations*, Applied Mathematical Sciences, Springer-Verlag, New York, 1993.

[23] Z. Han and H. L. Smith, Bacteriophage-resistant and bacteriophage-sensitive bacteria in a chemostat, *Mathematical Biosciences and Engineering*, **9** (2012), 737–765.

[24] S. B. Hsu, S. Hubbell and P. Waltman, A mathematical theory for single-nutrient competition in continuous cultures of micro-organisms, *Applied Mathematics*, **32** (1977), 366–383.

[25] S. B. Hsu, Limiting behavior for competing species, *SIAM Journal on Applied Mathematics*, **34** (1978), 760–763.

[26] P. Horvath and R. Barrangou, CRISPR/Cas the immune system of bacteria and archaea, *Science*, **327** (2010), 167–170.

[27] J. Iranzo, A. E. Lobkovsky and Y. I. Wolf, Evolutionary dynamics of the prokaryotic adaptive immunity system CRISPR-Cas in an explicit ecological context, *Journal of Bacteriology*, **195** (2013), 3834–3844.

[28] B. R. Levin, F. M. Stewart and L. Chao, Resource-limited growth, competition, and predation: A model, and experimental studies with bacteria and bacteriophage, *American Naturalist*, **111** (1977), 3–24.

[29] B. R. Levin, Nasty viruses, costly plasmids, population dynamics, and the conditions for establishing and maintaining CRISPR-mediated adaptive immunity in bacteria, *PLoS Genet*, **6** (2010), e1001171.

[30] B. R. Levin, S. Moineau and M. Bushman, The population and evolutionary dynamics of phage and bacteria with CRISPR-mediated immunity, *PLoS Genet*, **9** (2013), e1003312.

[31] T. Li, Analysis of bacterial immune system-A review, *Acta Microbiologica Ssinica*, **51** (2011), 1297–1303.

[32] M. Lin, H. F. Huo and Y. N. Li, A competitive model in a chemostat with nutrient recycling and antibiotic treatment, *Nonlinear Analysis: Real World Applications*, **13** (2012), 2540–2555.

[33] Y. Ma and H. Chang, A review on immune system of the bacteria and its self versus non-self discrimination, *Chinese Veterinary Science*, **42** (2012), 657–660.

[34] L. A. Marraffini and E. J. Sontheimer, Self versus non-self discrimination during CRISPR RNA-directed immunity, *Nature*, **463** (2010), 568–571.

[35] S. Matsuzaki, M. Rashel and J. Uchiyama, Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases, *Journal of Infection and Chemotherapy*, **11** (2005), 211–219.

[36] K. Northcott and M. Imran, Competition in the presence of a virus in an aquatic system: an SIS model in the chemostat, *Journal of Mathematical Biology*, **64** (2012), 1043–1086.

[37] L. Perko, *Differential Equations and Dynamical Systems,* Texts in Applied Mathematics, 7. Springer-Verlag, New York, 1993.

[38] L. M. Proctor and J. A. Fuhrman, Viral mortality of marine bacteria and cyanobacteria, *Nature*, **343** (1990), 60–62.

[39] J. Reeks, J. H. Naismith and M. F. White, CRISPR interference: A structural perspective, *Biochemical Journal*, **453** (2013), 155–166.

[40] G. Robledo, F. Grognard and J. L. Gouzé, Global stability for a model of competition in the chemostat with microbial inputs, *Nonlinear Analysis: Real World Applications*, **13** (2012), 582–598.

[41] K. D. Seed and D. W. Lazinski, A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity, *Nature*, **494** (2013), 489–491.

[42] H. L. Smith and H. R. Thieme, Persistence of bacteria and phages in a chemostat, *Journal of Mathematical Biology*, **64** (2012), 951–979.

[43] H. R. Thieme, Convergence results and a Poincaré-Bendixson trichotomy for asymptotically autonomous differential equations, *Journal of Mathematical Biology*, **30** (1992), 755–763.

[44] H. R. Thieme, Persistence under relaxed point-dissipativity with application to an endemic model, *SIAM J. Math. Anal.*,**24** (1993), 407–435.

[45] R. A. Usmani, *Applied Linear Algebra*, Marcel Dekker, New York , 1987.

[46] W. Wang and X. Zhao, An epidemic model in a patchy environment, *Mathematical Biosciences*, **190** (2004), 97–112.

[47] R. J. Weld, C. Butts and J. A. Heinemann, Models of phage growth and their applicability to phage therapy, *Journal of Theoretical Biology*, **227** (2004), 1–11.

[48] X. Zhao, *Dynamical Systems in Population Biology*, 2nd edition, Springer-Verlag, London, 2003.

E-mail address: 1040250727@qq.com

E-mail address: 527274397@qq.com

E-mail address: wendi@swu.edu.cn